Peginesatide
ESAs Increase the Risk of Death, Myocardial Infarction, Stroke, Venous Thromboembolism, Thrombosis of Vascular Access, and Tumor Progression or Recurrence
Chronic Kidney Disease
- In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL.
- No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks.
- Use the lowest peginesatide dose sufficient to reduce the need for red blood cell (RBC) transfusions.
Approved Risk Evaluation and Mitigation Strategies (REMS)
Patient Counseling Information
Medication Guides
Package Inserts
Additional Information
Updated February 2016